Prevents malaria. ANDA 213075, held by Alembic. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 213075 (Doxycycline Hyclate), held by Alembic, was first approved by FDA on Jan 3, 2022, with 2 approved supplements and 0 published complete response letters.
Doxycycline hyclate delayed-release tablets are a tetracycline-class drug indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 3, 2022 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 75MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 100MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 150MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 200MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Rx |
| Mar 26, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 26, 2026 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jan 3, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters